Miguel Prudêncio graduated in Biochemistry by the Faculty of Sciences of the University of Lisbon in 1993 and completed his PhD on Biochemistry by the University of East Anglia in 2000, followed by a post-doctoral period at the University of Leiden. During this period, he worked on metalloprotein characterization and protein-protein interactions. In 2004, he shifted his research focus to the field of malaria and became a post-doc in Maria Mota¿s research group at Instituto de Medicina Molecular (iMM). In 2008, he became a Staff Scientist of iMM¿s Malaria Unit and, in 2013, he became an independent Group Leader at iMM, heading the Prudêncio lab. He was appointed Invited Associate Professor of the Faculdade de Medicina da Universidade de Lisboa in March 2019, and completed his Habilitation to this Faculty in January 2023. Miguel¿s research interests focus on the investigation of Plasmodium liver stages and on the exploitation of their potential for anti-malarial intervention. He is guided by the conviction that the ambitious goal of malaria eradication requires the combination of the knowledge driven by fundamental investigation with the targeted approaches afforded by translational research. His research program includes unveiling novel aspects of the biology of Plasmodium infection, identifying drugs with antiplasmodial activity, establishing new experimental methodologies to study the malaria parasite, and investigating the reciprocal impact of concurrent infections with Plasmodium and other infectious agents. Among his ambitions is a desire to contribute to the development of a much-needed effective vaccine against malaria, which has led him to investigate the immunology of Plasmodium liver infection, and to develop and clinically validate a novel approach to whole-sporozoite vaccination against malaria. He has led research projects funded by by multiple National and International funding agencies or institutions, including Fundação para a Ciência e Tecnologia, the Bill and Melinda Gates Foundation, the Malaria Vaccine Initiative, the La Caixa Foundation, Merck KGaA, and the GSK-Tres Cantos Open Lab Foundation. Miguel is the author of over 150 scientific articles in international peer-reviewed journals, with over 6400 citations, an h-index of 42, and an i10 index of 108. He has earned multiple scientific and innovation prizes and awards, and is an inventor of several patents. He regularly lectures at undergraduate and graduate courses in various Faculties and Universities. As the COVID-19 pandemic emerged, Miguel was involved in setting up iMM's Task Force for SARS-CoV-2 diagnostics. He has a keen interest on COVID-19 vaccination and has addressed this issue on multiple occasions in webinars and in the media. https://miguelprudencio.com/ https://gimm.pt/pt-pt/o-nosso-trabalho/laboratorios/laboratorio-miguel-prudencio/